News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RiboNovix, Inc. Developing Anti-Infectives That Are Less Susceptible To Antibiotic Resistance


10/19/2005 5:11:45 PM

New biotechnology company, RiboNovix, Inc., is addressing the worsening problem of antibiotic-resistant bacteria by developing new anti-infectives that are less susceptible to drug resistance. Over the last few months, RiboNovix has completed an exclusive license agreement with Wayne State University for the rights to a novel functional genomics platform technology developed in the laboratories of Dr. Philip Cunningham, assembled a team of leading researchers in the field of antibiotic resistance, and been awarded a $346,066 Phase I SBIR grant by the National Institutes of Health.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES